Nephrocare Health Services Ltd
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
- Market Cap ₹ 7,426 Cr.
- Current Price ₹ 738
- High / Low ₹ 770 / 445
- Stock P/E 87.3
- Book Value ₹ 111
- Dividend Yield 0.00 %
- ROCE 15.3 %
- ROE 8.83 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 162% CAGR over last 5 years
Cons
- Stock is trading at 6.59 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE 1000 Nifty IPO BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 286 | 318 | 437 | 566 | 756 | 999 | 1,053 | |
| 248 | 302 | 389 | 465 | 589 | 774 | 817 | |
| Operating Profit | 37 | 16 | 49 | 101 | 167 | 225 | 236 |
| OPM % | 13% | 5% | 11% | 18% | 22% | 23% | 22% |
| 5 | 10 | 6 | 8 | 14 | 23 | 26 | |
| Interest | 7 | 10 | 16 | 20 | 21 | 60 | 56 |
| Depreciation | 34 | 42 | 47 | 56 | 72 | 91 | 96 |
| Profit before tax | 1 | -27 | -9 | 33 | 87 | 97 | 110 |
| Tax % | 31% | -21% | 37% | -6% | 23% | 21% | |
| 1 | -21 | -12 | 35 | 67 | 77 | 85 | |
| EPS in Rs | 3.40 | -106.93 | -58.69 | 169.82 | 321.87 | 7.66 | 4.19 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 32% |
| TTM: | 32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 162% |
| 3 Years: | 103% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 |
| Reserves | 245 | 391 | 384 | 409 | 579 | 1,096 |
| 140 | 119 | 200 | 271 | 261 | 80 | |
| 42 | 59 | 81 | 124 | 153 | 271 | |
| Total Liabilities | 428 | 571 | 666 | 806 | 994 | 1,467 |
| 192 | 205 | 239 | 356 | 396 | 517 | |
| CWIP | 2 | 43 | 34 | 1 | 6 | 6 |
| Investments | 0 | 0 | 0 | 0 | 51 | 178 |
| 234 | 322 | 393 | 449 | 542 | 767 | |
| Total Assets | 428 | 571 | 666 | 806 | 994 | 1,467 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 32 | 14 | 11 | 72 | 135 | 233 | |
| -62 | -130 | -76 | -52 | -125 | -392 | |
| 36 | 121 | 60 | 27 | 54 | 157 | |
| Net Cash Flow | 5 | 6 | -4 | 47 | 65 | -2 |
| Free Cash Flow | -29 | -64 | -62 | -8 | 35 | 113 |
| CFO/OP | 49% | 119% | 14% | 80% | 82% | 116% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 101 | 123 | 132 | 131 | 129 | 116 |
| Inventory Days | 65 | 50 | 67 | |||
| Days Payable | 56 | 70 | 63 | |||
| Cash Conversion Cycle | 110 | 103 | 137 | 131 | 129 | 116 |
| Working Capital Days | 26 | 55 | 19 | 56 | 27 | 42 |
| ROCE % | -4% | 1% | 8% | 14% | 15% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Machine Utilization Rate % |
|
|||||
| International Revenue Share % |
||||||
| Number of Active Guests (Patients) guests |
||||||
| Number of Dialysis Machines machines |
||||||
| Number of Dialysis Treatments (Sessions) sessions |
||||||
| Number of PPP (Public-Private Partnership) Clinics clinics |
||||||
| Revenue per Treatment (RPT) INR |
||||||
| Total Number of Dialysis Clinics clinics |
||||||
Extracted by Screener AI
Documents
Announcements
-
Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Grant Of Esops Under The Nephroplus Employee Stock Option Scheme 2026.
- NRC approved grant of 4,01,362 ESOPs on September 3, 2026 at ₹230 exercise price.
-
Announcement under Regulation 30 (LODR)-Acquisition
- NPHSK LLP to acquire 100% of Dialysis Center Almaty LLP for KZT 561.66 million.
-
Disclosure Under Regulation 30 Of SEBI Listing Regulations
- Uzbekistan tax department raised ₹14.79 crore assessment and penalty on NCA for 2023-25; company plans appeal.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Transcripts for the investors Earning call held on August 12, 2026.
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
- Subsidiary acquired dialysis center assets in Abuyog, Leyte, Philippines for PhP 75 million on August 17, 2026.
Annual reports
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
Business Profile[1]
Nephrocare Health Services Limited (NHSL) is India’s largest dialysis-care provider offering a full spectrum of renal-care services haemodialysis, peritoneal dialysis, home haemodialysis, dialysis-on-call, dialysis-on-wheels, pharmacy support, diagnostics, and wellness management. It operates through captive hospital-based clinics, standalone centres, and large Public-Private Partnership (PPP) units.